Aclaris Therapeutics Q3 revenue beats estimates, net loss narrows
I'm PortAI, I can summarize articles.
Aclaris Therapeutics reported Q3 revenue of $3.30 million, exceeding analyst expectations of $1.59 million, despite a year-over-year decline. The net loss narrowed to $14.6 million, better than the anticipated $15.8 million. The company announced positive Phase 2a trial results for ATI-2138 in atopic dermatitis and plans further trials in 2026. Analysts maintain a "buy" rating on the stock, with a 12-month price target of $7.00, reflecting a potential upside of 67.7% from its recent closing price of $2.26.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments